amarin
AMARIN TECHNOLOGIES S.A.U.

LIST OF PRODUCTS

	PRODUCT	STRENGTHS AND DOSAGES	THERAPEUTIC USE
Marketed Product	FENTANYL TDS	25, 50, 75, 100 mcg/h	Management of pain in opiod-tolerant patients
	RIVASTIGMINE TDS *	4.6; 9.5 and 13.3 mg/24 h	Alzheimer disease. Dementia associated with Parkinson disease
	BUPRENORPHINE TDS *	5; 7.5; 10; 15 and 20 mcg/h	Moderate to severe chronic pain
	ESTRADIOL GEL	0.06%	Hormonal replacement therapy
	TESTOSTERONE GEL*	1%	Hormonal replacement therapy
	DICLOFENAC Sodium Gel 1%	0,01	Osteoarthritis,soft-tissue rheumatism, traumatisms
BE Proved	ROTIGOTINE TDS	1; 2; 3; 4; 6 y 8 mg/24h	Parkinson disease
Pilot PK BE	SELEGILINE TDS *	6; 9 and 12 mg/d	Major depressive disorders
	METHYLPHENIDATE TDS *	10; 15; 20 and 30 mg/9 hours	Attention Deficit Hyperactivity Disorder (ADHD)
Pharmaceutical Development Stage	SILDENAFIL OTF	50 mg	Erectile Dysfunction
	TADALAFIL OTF	2.5; 5; 10; 20 mg	Benign Prostatic Hyperplasia; Erectile dysfunction
	VITAMIN D3 OTF	2000; 7000; 10000; 20000; 60000 IU	Vitamin D deficiency; osteoporosis/osteomalacia prevention/treatment
	MONTELUKAST OTF	4; 5; 10 mg	Asthma, allergic rhinitis, prevention of exercise-induced bronchospasm.
	RIVASTIGMINE Multidays TDS (Twice-weekly)	4.6; 9.5 and 13.3 mg/24 h	Alzheimer disease. Dementia associated with Parkinson disease
	RIVASTIGMINE Multidays TDS (Weekly)	4.6; 9.5 and 13.3 mg/24 h	Alzheimer disease. Dementia associated with Parkinson disease
	ROTIGOTINE Multiday TDS	1; 2; 3; 4; 6 y 8 mg/24h	Parkinson disease
	DONEPEZIL Multidays TDS	5; 10 mg/24 hours	Alzheimer disease
	Proyecto AT#123 - TDS	TBC	Moderate to severe chronic pain
	OPIOID ABUSE DETERRENT TDS	TBC	Management of pain in opiod-tolerant patients
	IBUPROFEN TDS	200 mg	Short-term symptomatic treatment of local pain in acute muscular strain
	LIDOCAINE TDS	5%	Pain relief associated with post-herpetic neuralgia

*** More efficient product than RLD (Lower drug content and smaller patch size)**